Verified factor-similar pair

RZG vs SCHA

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
85
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • SCHA has the higher backtested relative Sharpe (0.906 vs 0.886).
  • SCHA has the lower published fee (0.04% vs 0.35%).
  • RZG is cheaper on dividend valuation (113 vs 133, where 100 is each fund's historical median).
  • SCHA has the stronger regression fit (adjusted R-squared 0.985 vs 0.910).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

RZG

Invesco S&P Smallcap 600 Pure Growth ETF
SMB
Adj. R2
0.910
Rel. Sharpe
0.886
Mkt beta
1.01
AUM
US$111M
MER
0.35%
Valuation
113

SCHA

Schwab U.S. Small-Cap ETF
SMB
Adj. R2
0.985
Rel. Sharpe
0.906
Mkt beta
1.03
AUM
US$21.0B
MER
0.04%
Valuation
133

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
RZG
+0.98
|t|
+18.2
SCHA
+0.74
|t|
+34.7
diff +0.24
HML
RZG
+0.06
|t|
+1.2
SCHA
+0.12
|t|
+5.8
diff -0.06
RMW
RZG
+0.13
|t|
+2.0
SCHA
-0.08
|t|
-3.3
diff +0.21
CMA
RZG
-0.08
|t|
-1.1
SCHA
-0.03
|t|
-0.8
diff -0.06
UMD
RZG
+0.00
|t|
+0.0
SCHA
+0.05
|t|
+3.2
diff -0.05

Why This Pair Matches

Exposure level
81
Exposure shape
98
Mkt beta diff
0.02
Rel. Sharpe diff
0.020

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

RZG fund page SCHA fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.